SG11201901146SA - Indazole compounds for use in tendon and/or ligament injuries - Google Patents
Indazole compounds for use in tendon and/or ligament injuriesInfo
- Publication number
- SG11201901146SA SG11201901146SA SG11201901146SA SG11201901146SA SG11201901146SA SG 11201901146S A SG11201901146S A SG 11201901146SA SG 11201901146S A SG11201901146S A SG 11201901146SA SG 11201901146S A SG11201901146S A SG 11201901146SA SG 11201901146S A SG11201901146S A SG 11201901146SA
- Authority
- SG
- Singapore
- Prior art keywords
- novartis
- basel
- postfach
- research
- international
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398869P | 2016-09-23 | 2016-09-23 | |
| PCT/IB2017/055735 WO2018055550A1 (en) | 2016-09-23 | 2017-09-21 | Indazole compounds for use in tendon and/or ligament injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901146SA true SG11201901146SA (en) | 2019-04-29 |
Family
ID=60084023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901146SA SG11201901146SA (en) | 2016-09-23 | 2017-09-21 | Indazole compounds for use in tendon and/or ligament injuries |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US10112907B2 (el) |
| EP (1) | EP3515894B1 (el) |
| JP (1) | JP7007374B2 (el) |
| KR (1) | KR102490953B1 (el) |
| CN (1) | CN109715608B (el) |
| AR (1) | AR109688A1 (el) |
| AU (1) | AU2017332867B2 (el) |
| BR (1) | BR112019005578A2 (el) |
| CA (1) | CA3033249A1 (el) |
| CL (1) | CL2019000727A1 (el) |
| CO (1) | CO2019002616A2 (el) |
| CR (1) | CR20190145A (el) |
| CU (1) | CU24553B1 (el) |
| CY (1) | CY1124301T1 (el) |
| DK (1) | DK3515894T3 (el) |
| DO (1) | DOP2019000071A (el) |
| EA (1) | EA038510B1 (el) |
| EC (1) | ECSP19019589A (el) |
| ES (1) | ES2878585T3 (el) |
| HR (1) | HRP20211006T1 (el) |
| HU (1) | HUE054910T2 (el) |
| IL (1) | IL265066B (el) |
| JO (1) | JOP20190054B1 (el) |
| LT (1) | LT3515894T (el) |
| MX (1) | MX2019003362A (el) |
| MY (1) | MY196425A (el) |
| PE (1) | PE20190657A1 (el) |
| PH (1) | PH12019500327A1 (el) |
| PL (1) | PL3515894T3 (el) |
| PT (1) | PT3515894T (el) |
| RS (1) | RS62145B1 (el) |
| RU (1) | RU2749547C2 (el) |
| SG (1) | SG11201901146SA (el) |
| SI (1) | SI3515894T1 (el) |
| TW (1) | TWI651308B (el) |
| UY (1) | UY37412A (el) |
| WO (1) | WO2018055550A1 (el) |
| ZA (1) | ZA201900860B (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190053A1 (ar) * | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| MX2021008303A (es) | 2019-01-11 | 2021-10-13 | Novartis Ag | Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa. |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0115102B1 (pt) * | 2000-11-02 | 2013-11-26 | Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos | |
| JP2004518662A (ja) | 2000-12-19 | 2004-06-24 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｇｓｋ−３阻害剤としてのピラゾロ［３，４−ｃ］ピリジン |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| FR2871158A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| DE102004028862A1 (de) * | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| WO2008104473A2 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
| AU2008262038A1 (en) | 2007-06-08 | 2008-12-18 | AbbVie Deutschland GmbH & Co. KG | 5-heteroaryl substituted indazoles as kinase inhibitors |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| JP2013542960A (ja) | 2010-11-08 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 脂肪酸シンターゼ阻害剤 |
| BR112013021537B1 (pt) * | 2011-02-24 | 2021-08-10 | Nerviano Medical Sciences S.R.L. | Derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase |
| WO2012158810A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
| TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途 |
-
2017
- 2017-09-21 SI SI201730834T patent/SI3515894T1/sl unknown
- 2017-09-21 US US15/711,984 patent/US10112907B2/en active Active
- 2017-09-21 DK DK17784404.0T patent/DK3515894T3/da active
- 2017-09-21 EP EP17784404.0A patent/EP3515894B1/en active Active
- 2017-09-21 AR ARP170102603A patent/AR109688A1/es unknown
- 2017-09-21 RS RS20210833A patent/RS62145B1/sr unknown
- 2017-09-21 UY UY0001037412A patent/UY37412A/es unknown
- 2017-09-21 EA EA201990766A patent/EA038510B1/ru not_active IP Right Cessation
- 2017-09-21 PL PL17784404T patent/PL3515894T3/pl unknown
- 2017-09-21 CN CN201780057662.4A patent/CN109715608B/zh active Active
- 2017-09-21 PE PE2019000680A patent/PE20190657A1/es unknown
- 2017-09-21 PT PT177844040T patent/PT3515894T/pt unknown
- 2017-09-21 MX MX2019003362A patent/MX2019003362A/es unknown
- 2017-09-21 KR KR1020197010512A patent/KR102490953B1/ko active IP Right Grant
- 2017-09-21 CA CA3033249A patent/CA3033249A1/en active Pending
- 2017-09-21 BR BR112019005578A patent/BR112019005578A2/pt active Search and Examination
- 2017-09-21 ES ES17784404T patent/ES2878585T3/es active Active
- 2017-09-21 CR CR20190145A patent/CR20190145A/es unknown
- 2017-09-21 JO JOP/2019/0054A patent/JOP20190054B1/ar active
- 2017-09-21 RU RU2019111883A patent/RU2749547C2/ru active
- 2017-09-21 MY MYPI2019000713A patent/MY196425A/en unknown
- 2017-09-21 CU CU2019000028A patent/CU24553B1/es unknown
- 2017-09-21 AU AU2017332867A patent/AU2017332867B2/en active Active
- 2017-09-21 WO PCT/IB2017/055735 patent/WO2018055550A1/en unknown
- 2017-09-21 JP JP2019515633A patent/JP7007374B2/ja active Active
- 2017-09-21 LT LTEP17784404.0T patent/LT3515894T/lt unknown
- 2017-09-21 SG SG11201901146SA patent/SG11201901146SA/en unknown
- 2017-09-21 HU HUE17784404A patent/HUE054910T2/hu unknown
- 2017-09-21 TW TW106132361A patent/TWI651308B/zh active
-
2019
- 2019-02-11 ZA ZA2019/00860A patent/ZA201900860B/en unknown
- 2019-02-15 PH PH12019500327A patent/PH12019500327A1/en unknown
- 2019-02-26 IL IL265066A patent/IL265066B/en active IP Right Grant
- 2019-03-20 EC ECSENADI201919589A patent/ECSP19019589A/es unknown
- 2019-03-20 DO DO2019000071A patent/DOP2019000071A/es unknown
- 2019-03-20 CL CL2019000727A patent/CL2019000727A1/es unknown
- 2019-03-21 CO CONC2019/0002616A patent/CO2019002616A2/es unknown
-
2021
- 2021-06-24 HR HRP20211006TT patent/HRP20211006T1/hr unknown
- 2021-07-05 CY CY20211100601T patent/CY1124301T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201908097YA (en) | Pyrimidine derivatives as pge2 receptor modulators | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201810561YA (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
| SG11201900651PA (en) | Combination of fxr agonists | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |